Driving Cell and Gene Therapy Innovation: uBriGene at ASGCT 2025

uBriGene is proud to announce our participation at the 28th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 13–17, 2025 in vibrant New Orleans, LA. 

As a leading integrated Contract Development and Manufacturing Organization (CDMO), uBriGene is committed to supporting the development and commercialization of advanced therapies through scientific excellence and innovation-driven solutions.

This year, uBriGene will exhibit at booth #2145, where our team will showcase our comprehensive CDMO capabilities across the entire product development life cycle, including technology transfer, process and analytical development, scale-up, GMP-readiness, and regulatory strategy. 

Beyond the exhibition floor, uBriGene is honored to contribute to the ASGCT scientific program with one oral presentation and three poster presentations, each highlighting recent advancements from our research and development teams.

Oral Presentation 

Evaluation of Quality Control Methods for Circular RNA Purity and Integrity: SEC-HPLC, CE, and RP-HPLC

📅 8:00 AM on May 17, 2025 at Conference Center, room 288–290

This study explores critical quality attributes of circular RNA products and compares multiple analytical methods to enhance their characterization, supporting the growing interest in circular RNA as a next-generation therapeutic modality.

Poster Presentations

Poster #621: T-Cell Gene Editing via Integration-Free LNP-Mediated Delivery of gRNA and CRISPR Enzyme
Poster #1844: A Novel AAV TCID50 Testing Method Using Replication-Deficient Helper Adenovirus and Inducible 293 Cell
Poster #1676: A Novel HPLC-ELSD Method for Lipid Identification and Quantification in mRNA-LNP Complexes

📅 6:00 PM on May 13 (#621), and 5:30 PM on May 15 (#1844, #1676) at Hall I2

These presentations reflect uBriGene’s relentless pursuit of innovation and our mission to enhance the quality, safety, and scalability of advanced therapies.

Together, these presentations reflect uBriGene’s relentless drive to deliver cutting-edge technologies that advance cell and gene therapy development. Our commitment to innovation not only fuels scientific progress but also strengthens our mission as a trusted CDMO partner for developers worldwide.

We look forward to engaging with our peers, collaborators, and potential partners at ASGCT 2025, booth #2145. Whether you're in early discovery or preparing for GMP manufacturing, we invite you to meet the uBriGene team in New Orleans and learn how our integrated solutions can accelerate your journey from idea to impact.

Learn more about the event at ASGCT 28th Annual Meeting